ADMA - ADMA BIOLOGICS, INC.

10.88
-0.130   -1.195%

Share volume: 4,878,793
Last Updated: 04-20-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$11.01
-0.13
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
66%
Profitability 81%
Dept financing 26%
Liquidity 75%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.30%
1 Month
-19.94%
3 Months
-37.33%
6 Months
-26.06%
1 Year
-44.60%
2 Year
75.48%
Key data
Stock price
$10.88
P/E Ratio 
0.00
DAY RANGE
$10.68 - $11.05
EPS 
$0.62
52 WEEK RANGE
$7.21 - $25.67
52 WEEK CHANGE
-$49.14
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
0.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,550,108
AVERAGE 30 VOLUME 
$10,667,966
Company detail
CEO: Adam S. Grossman
Region: US
Website: admabiologics.com
Employees: 530
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

ADMA Biologics, Inc. engages in developing, manufacturing, and marketing specialty plasma-derived biologics. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI) and ASCENIV. Nabi-HB for the. treatment of acute exposure to blood containing Hepatitis B surface antigen.

Recent news